Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- 1 April 2012
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 379 (9825), 1489-1497
- https://doi.org/10.1016/s0140-6736(12)60204-9
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
This publication has 18 references indexed in Scilit:
- The Impact of Non-Severe Hypoglycemic Events on Work Productivity and Diabetes ManagementValue in Health, 2011
- Insulin Degludec in Type 1 DiabetesDiabetes Care, 2011
- Standards of Medical Care in Diabetes—2011Diabetes Care, 2011
- Hypoglycemia Unawareness Is Associated With Reduced Adherence to Therapeutic Decisions in Patients With Type 1 DiabetesDiabetes Care, 2009
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- How hypoglycaemia can affect the life of a person with diabetesDiabetes/Metabolism Research and Reviews, 2008
- Refining basal insulin therapy: what have we learned in the age of analogues?Diabetes/Metabolism Research and Reviews, 2007
- Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 DiabetesThe New England Journal of Medicine, 2005
- Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetesCurrent Medical Research and Opinion, 2005
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusThe New England Journal of Medicine, 1993